Mesenchymal Stromal Cells for Degenerative Meniscus Injury
Status:
Completed
Trial end date:
2017-05-02
Target enrollment:
Participant gender:
Summary
The present proposal has the objective to assess whether the addition of autologous ex vivo
expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury
rehabilitation program is contributing in creating the proper healing environment for the
meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of
the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The
conduction of this clinical trial will, in addition of having the aim of improving the
patient's quality of life, contribute to consolidate an emerging new type of therapy which is
still under development.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Banc de Sang i Teixits
Collaborators:
Hospital Universitari Quirón Dexeus Ministerio de Sanidad, Servicios Sociales e Igualdad